Clinical Trial: Interventional Therapy Combined with Camrelizumab and Apatinib in the Treatment of Intermediate-Advanced Hepatocellular Carcinoma After Progression on First-Line Targeted-Immunotherapy: A Single-Arm, Phase II Clinical Study (China)

China, Sept. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Interventional Therapy Combined with Camrelizumab and Apatinib in the Treatment of Intermediate-Advanced Hepatocellular Carcinoma After Progression on First-Line Targeted-Immunotherapy: A Single-Arm, Phase II Clinical Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132596

Registration Time: 2026/09/16

Type: Interventional study

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342219

Published by HT Digital Content Services w...